Enzychem Lifesciences Corporation (183490.KQ)
KRW 1329.0
(-2.71%)
KRW 1329.0
(-2.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 76.03 Billion | 26.63 Billion | 22.97 Billion | 25.81 Billion | 31.46 Billion | 31.03 Billion |
| Cost of Revenue | 72.74 Billion | 25.01 Billion | 23.35 Billion | 24.49 Billion | 29.34 Billion | 27.18 Billion |
| Gross Profit | 3.29 Billion | 1.61 Billion | -376.78 Million | 1.32 Billion | 2.12 Billion | 3.85 Billion |
| Operating Expenses | 18.7 Billion | 16.42 Billion | 20.37 Billion | 19.15 Billion | 18.52 Billion | 18.82 Billion |
| Selling, General and Administrative Expenses | 12.59 Billion | 9.72 Billion | 10.87 Billion | 7.56 Billion | 7.08 Billion | 8.65 Billion |
| Research and Development Expenses | 5.43 Billion | 6.69 Billion | 9.5 Billion | 12.86 Billion | 11.44 Billion | 10.16 Billion |
| Other Expenses | - | 14.29 Million | 312.94 Million | 1.27 Billion | -374.62 Thousand | -6.41 Million |
| Cost and Expenses | 90.39 Billion | 41.44 Billion | 43.72 Billion | 43.64 Billion | 47.87 Billion | 46 Billion |
| Operating Income | -14.35 Billion | -14.8 Billion | -20.75 Billion | -17.82 Billion | -16.4 Billion | -14.97 Billion |
| Interest Expense | 620.09 Million | 10.03 Billion | 9.5 Billion | 1.42 Billion | 158.26 Million | 110.49 Million |
| Income Tax Expense | -476.29 Million | -488.27 Million | -1.63 Billion | -1.72 Billion | 203.54 Million | 139.26 Million |
| Earnings before Tax | -9.87 Billion | -25.57 Billion | -29.49 Billion | -19.18 Billion | -17.38 Billion | -14.28 Billion |
| Net Income | -9.32 Billion | -25.09 Billion | -27.86 Billion | -17.5 Billion | -16.87 Billion | -14.42 Billion |
| Earnings Per Share Basic | -109.81 | -318.36 | -558.47 | -284.83 | -284.31 | -251.00 |
| Earnings Per Share Diluted | -109.81 | -318.36 | -558.47 | -284.83 | -284.31 | -251.00 |
| Weighted Average Shares Outstanding | 84.92 Million | 78.81 Million | 49.89 Million | 61.46 Million | 59.36 Million | 57.45 Million |
| Weighted Average Shares Outstanding (Diluted) | 84.92 Million | 78.81 Million | 49.89 Million | 61.46 Million | 59.36 Million | 57.45 Million |
| Gross Margin | 0.04 | 0.06 | -0.02 | 0.05 | 0.07 | 0.12 |
| EBIT Margin | -0.08 | -0.47 | -0.81 | -0.61 | -0.46 | -0.43 |
| Profit Margin | -0.12 | -0.94 | -1.21 | -0.68 | -0.54 | -0.46 |
| EBITDA | -5.77 Billion | -13.15 Billion | -17.87 Billion | -15.71 Billion | -14.45 Billion | -12.63 Billion |
| Earnings Before Tax Margin | -0.19 | -0.56 | -0.90 | -0.69 | -0.52 | -0.48 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 19.6 Billion | 22.24 Billion | 23.21 Billion | 76.03 Billion | 19.76 Billion | 17.42 Billion |
| Cost of Revenue | 18.56 Billion | 20.63 Billion | 22.22 Billion | 72.74 Billion | 19.24 Billion | 16.78 Billion |
| Gross Profit | 1.04 Billion | 1.6 Billion | 984.66 Million | 3.29 Billion | 519 Million | 645.91 Million |
| Operating Expenses | 4.67 Billion | 3.76 Billion | 4.58 Billion | 18.02 Billion | 4.76 Billion | 4.47 Billion |
| Selling, General and Administrative Expenses | 3.55 Billion | 2.68 Billion | 3.1 Billion | - | 3.8 Billion | 3.13 Billion |
| Research and Development Expenses | 1.11 Billion | 1.07 Billion | 1.47 Billion | - | 957.32 Million | 1.33 Billion |
| Other Expenses | -4.91 Billion | 77.51 Million | 8.6 Million | 53.69 Million | 14.28 Million | 23.5 Million |
| Cost and Expenses | 23.23 Billion | 24.39 Billion | 26.81 Billion | 90.77 Billion | 24.01 Billion | 21.26 Billion |
| Operating Income | -3.63 Billion | -2.15 Billion | -3.6 Billion | -14.73 Billion | -4.24 Billion | -3.83 Billion |
| Interest Expense | 60.29 Million | 63.27 Million | 70.34 Million | 620.09 Million | 64.5 Million | 75.79 Million |
| Income Tax Expense | -11.15 Million | -11.16 Million | -448.99 Million | -476.29 Million | -17.51 Million | -31.65 Million |
| Earnings before Tax | -3.36 Billion | -776.36 Million | -2.22 Billion | -9.9 Billion | -2.81 Billion | -2.52 Billion |
| Net Income | -3.36 Billion | -1.08 Billion | -1.83 Billion | -9.32 Billion | -2.63 Billion | -2.45 Billion |
| Earnings Per Share Basic | -40.41 | -12.80 | -21.54 | - | -30.97 | -28.85 |
| Earnings Per Share Diluted | -40.41 | -12.80 | -21.54 | - | -30.97 | -28.85 |
| Weighted Average Shares Outstanding | 83.15 Million | 85.06 Million | 85.06 Million | 84.92 Million | 85.06 Million | 85.06 Million |
| Weighted Average Shares Outstanding (Diluted) | 83.15 Million | 85.06 Million | 85.06 Million | 84.92 Million | 85.06 Million | 85.06 Million |
| Gross Margin | 0.05 | 0.07 | 0.04 | 0.04 | 0.03 | 0.04 |
| EBIT Margin | -0.14 | -0.06 | -0.12 | - | -0.17 | -0.16 |
| Profit Margin | -0.17 | -0.05 | -0.08 | -0.12 | -0.13 | -0.14 |
| EBITDA | -2.75 Billion | -1.25 Billion | -2.78 Billion | - | -3.33 Billion | -2.87 Billion |
| Earnings Before Tax Margin | -0.19 | -0.10 | -0.16 | -0.19 | -0.21 | -0.22 |
OBIO
MDPR
DIANATEA
CZT
PX
SABTNL